assemblybio.com (ASMB) Company Sales Revenue

assemblybio.com - graphic logo of issuer ASMB

Assembly Biosciences develops advanced antiviral agents for the cellular eradication of hepatitis B. Business revenues rely on the commercialization of next-generation therapies. Financial stability is supported by milestone payments from global partners. The company's gross sales level reflects demand dynamics, where the current mark equals 0.07, serving as an indicator of the assets' fundamental condition.

Assembly Biosciences (ASMB): Company Revenue from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Assembly Biosciences, Inc. (ASMB)

- market price and analyst price targets:
Market Price Assembly Corp|ASMB - Price Target Chart
- market capitalization details:
Market Value Assembly Biosciences, Inc.|ASMB - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Assembly Biosciences|ASMB - Company Book Value|Market Capitalization to Book Value assemblybio.com|ASMB - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Coefficient Assembly Biosciences|ASMB - Long-Term Debt to Capital|Current Liabilities to Capital Assembly Bio|ASMB - Company Debts|Debt to Book Value Assembly Biosciences, Inc.|ASMB - Company Long-Term Debts|Company Short-Term Debt Assembly Biosciences|Quick Liquidity assemblybio.com
- net income and valuation ratios data:
ASMB - Net Income|Expected Net Profit Assembly Biosciences|ASMB - Price to Earnings Ratio|Future Price to Earnings Multiple assemblybio.com|ASMB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assembly Biosciences, Inc.|ASMB - Operating profit EBITDA|Net earnings per share for the last four quarters Assembly Biosciences|ASMB - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months assemblybio.com|ASMB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Assembly Biosciences
- sales volume and revenue indicators:
ASMB - Revenue and Sales Volume|Company Future Sales Volume Assembly Corp|ASMB - P/S Multiple|Market Cap to Expected Sales Ratio Assembly Biosciences, Inc.
Comprehensive company analysis:ASMB Assembly Corp
Manufactured product of Assembly Biosciences

This metric captures the aggregate cash flow from product sales, reflecting actual market demand for goods. Rising values confirm business expansion, while stagnation signals distribution challenges. By analyzing the commercial sales figures of the company, an investor can promptly diagnose deviations from the business plan. For Assembly Biosciences (ASMB), this metric is critical due to the fierce competition with pharma behemoths in the hepatitis B therapy segment. Success in this scientific race directly determines the financial stability of the issuer.

Key competitors

Company Total Revenue Arrowhead Corp ARWR|Company Revenue Mirum Pharmaceuticals (MIRM)|DVAX (Dynavax Technologies Corporation) - Company Sales Revenue|Revenue and Sales Volume ABUS (Arbutus Biopharma Corporation)|Revenue and Sales Volume Inventiva SA IVA|GYRE - Company Revenue|Company Gross Revenue Galectin Therapeutics GALT|genfit.com (GNFT) - Company Revenue|DRRX - Company Gross Revenue|ALGS (Aligos Therapeutics Inc.) - Revenue and Sales Volume|Company Total Revenue BioVie Pharma BIVI|Company Revenue Galmed Pharmaceuticals (GLMD)|Company Sales ENDRA Corp NDRA|Revenue and Sales Volume HEPA (Hepion Pharmaceuticals, Inc.)